Journal · Updated 2026-08-11

Tirzepatide vs Semaglutide in 2026: The Head-to-Head Trial, Every Price, One Framework

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

Two molecules, one-and-a-half mechanisms

Semaglutide is a GLP-1 receptor agonist: it activates one incretin pathway — slowing gastric emptying, boosting insulin response, and quieting appetite signaling in the brain. Tirzepatide activates that same GLP-1 pathway and adds a second, the GIP receptor, in a single engineered 39-amino-acid peptide. The dual action appears to be why tirzepatide's numbers run ahead: in their separate pivotal trials, tirzepatide posted 15.0, 19.5, and 20.9 percent average loss at 5, 10, and 15 mg over 72 weeks (SURMOUNT-1), while semaglutide 2.4 mg posted 14.9 percent over 68 weeks (STEP 1). Cross-trial comparisons are treacherous — different populations, different durations — which is what makes SURMOUNT-5 matter: same trial, same clock, head to head, and the gap held at 20.2 versus 13.7 percent. Read it with its caveats attached: open-label, funded by tirzepatide's manufacturer, and studying the FDA-approved brand products — not the compounded versions most price-shoppers are actually comparing, to which the results transfer by analogy only.

The price ladders, side by side

Compounded, month-to-month, all-in: semaglutide runs from bmiMD's one twenty-nine through Oak's one thirty-three, NexLife's one thirty-nine promotional, and the one-forty-nine cluster; tirzepatide starts forty dollars higher at NexLife's one sixty-nine promotional, then Henry Meds and bmiMD at one seventy-nine. Twelve-month equivalents: semaglutide reaches ninety-nine at three programs (bmiMD and HealthRX billed monthly, Trimi billed as eleven eighty-eight upfront); tirzepatide reaches one twenty-five (Trimi, LumiMeds — both billed around fifteen hundred upfront) and one thirty-nine billed monthly (bmiMD, NexLife promotional). Brand: oral Wegovy from one forty-nine, the Wegovy pen at three forty-nine (one ninety-nine introductory on the first two starter fills through the end of 2026), against Zepbound at two ninety-nine to four forty-nine by dose with the 45-day refill rule. At every rung, semaglutide is forty to two hundred seventy dollars a month cheaper than the tirzepatide directly above it.

Cost per percentage point: an illustrative calculation

Treat this as a sketch, not a clinical tool. A year at the cheapest committed tirzepatide (fifteen hundred to sixteen sixty-eight dollars) against an average trial-grade loss around twenty percent implies roughly seventy-five to eighty-five dollars per percentage point of body weight. A year at the cheapest committed semaglutide (eleven eighty-eight) against roughly fourteen to fifteen percent implies about eighty to eighty-five dollars per point. On brand pricing the same arithmetic yields roughly two hundred seventy dollars per point for Zepbound and two hundred eighty to three hundred for the Wegovy pen. The honest reading: at the compounded floor the two molecules cost about the same per unit of average result, and the real decision is absolute — total budget, total weight-loss goal, and tolerability — not efficiency. And every input on the results side belongs to brand-product trials; individual response varies enormously around every average.

How a clinician actually chooses

The pattern in practice: more weight to lose, or an inadequate response to semaglutide, pushes toward tirzepatide — the ceiling is simply higher, and switching semaglutide-to-tirzepatide after a plateau is a common, well-trodden path. A tighter budget, a smaller goal, or specific comorbidity evidence pushes toward semaglutide — it carries the SELECT cardiovascular-outcomes data in its column, costs less at every tier, and its oral form is the only sub-one-fifty FDA-approved option in the entire class. Side-effect profiles are similar in kind (GI effects dominating the first weeks of titration, the same thyroid C-cell boxed warning and MTC/MEN-2 contraindications on both labels), so tolerability usually gets discovered rather than predicted. None of this is prescribing advice; it's the shape of the decision you should expect a prescriber to walk you through — and if a telehealth intake doesn't ask about your history, your goal, and your prior GLP-1 exposure before recommending a molecule, that's information about the intake.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.